Showing 15 posts of 853 posts found.

NICE rejects Pfizer’s Vyndaqel for treating rare heart condition

May 12, 2021
Research and Development NICE, Pfizer, Vyandaqel

NICE has published final guidance today which rejects tafamidis, also known as Vyndaqel, for treating rare heart condition transthyretin amyloidosis …

NICE rejects Merck Serono’s Bavencio for urothelial cancer

May 10, 2021
Sales and Marketing MSD, Merck, NHS, NICE, cancer treatment, pharma, pharma news

The use of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy is not recommended by …

NICE finds more SMA patients eligible for £75,000 a vial drug

May 4, 2021
Manufacturing and Production, Sales and Marketing NICE, sma

NICE has announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen, …

NICE to join GetReal Institute alongside nine key healthcare players

April 28, 2021
Research and Development EU, NICE, rwe

NICE has announced it will join with nine other organisations to form the GetReal Institute, a not-for-profit multi-stakeholder enterprise, as …

NICE updates guidelines on atrial fibrillation based on new evidence

April 27, 2021
Manufacturing and Production NICE

NICE has updated its guideline on the diagnosis and management of atrial fibrillation (AF) based on new evidence found since …

Novartis multiple sclerosis treatment recommended by NICE

April 20, 2021
Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news

NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …

NICE launch ambitious five-year patient access strategy

April 19, 2021
Sales and Marketing NICE

NICE has unveiled its five-year plan to speed up patients’ access to the latest and most effective treatments with increased …


First approved C5 complement inhibitor recommended by NICE for NHS use

April 15, 2021

NICE has recommended Ultomiris (ravulizumab) for use in the NHS for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adult …

NICE recommends CBT, acupuncture, and anti-depressants for chronic pain

April 7, 2021
Research and Development NICE, antidepressant, chronic pain

A new NICE guideline on the assessment and management of chronic primary pain does not recommend the prescription of painkillers, …

NICE recommends Kineret for Still’s disease treatment

April 1, 2021

Sobi has today announced a NICE recommendation of Kineret (anakinra) as a first-line biologic therapeutic option for still’s disease, including …


The Truth Behind the £1.8 Million Drug

March 31, 2021
Manufacturing and Production FDA, NHS, NICE

As NICE approves the most expensive drug ever for use by the NHS, Jack Goddard takes a look at drug …

NICE recommends new triple therapy for multiple myeloma patients

March 19, 2021
Medical Communications NHS England, NICE, oncology

A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma, following a …

AstraZeneca & MSD ovarian cancer drug combination approved by NICE

March 19, 2021
Medical Communications AstraZeneca, MSD, NICE, oncology

A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …


NICE recommends Daiichi Sankyo’s cholesterol-lowering treatments for NHS England use

March 18, 2021
Daiichi Sankyo, NICE, cholesterol

NICE has recommended Daiichi Sankyo’s bempedoic acid and bempedoic acid/ezetimibe for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed …

NICE recommends £1.79m gene therapy for spinal muscular atrophy in babies

March 8, 2021
Sales and Marketing NICE, spinal muscular atrophy

NICE is set to approve a new and potentially curative one-off gene therapy for babies with the rare genetic disorder …

Latest content